News

People with Parkinson’s disease may have higher levels of selenium — a mineral with antioxidant properties — in their cerebrospinal fluid, the liquid that surrounds the brain and spinal cord, a study suggests. The research, “Selenium level does not differ in blood but…

A new potential target for treating Parkinson’s, a protein named Drp1, has been identified using a rat model of the disease, a study reported. The target was found to play a central role in the underlying cause of the degeneration and inflammation of nerve cells…

Likely cognitive decline, dementia risk, and the severity of motor symptoms in Parkinson’s disease might be tracked by measuring the amount of iron content in the brain, a study reports. These finding were described in the study “Brain iron deposition is linked with cognitive severity in Parkinson’s disease,”…

Scientists have developed a new cellular model that can help reconstruct the entire process of Lewy body formation — a key event that underlies neurodegeneration in Parkinson’s disease — and that could potentially be used to evaluate the effect of therapeutics on the toxic protein buildup observed during this…

Annovis Bio’s lead investigative therapy ANVS401 (also known as Posiphen) targeting protein buildup in the brain has been granted a U.S. patent as a way of treating Parkinson’s disease, Lewy body dementia, and other Lewy body disorders. The company, previously known as QR Pharma,…

Aggregates of the Parkinson’s disease-associated protein alpha-synuclein can spread from the gut to the brain in mice, but this process is dependent on aging, likely as a result of altered protein dynamics, a new study suggests. The study, “Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology…

Scientists have uncovered a new therapeutic molecule, called BT13, that can get to the brain to boost dopamine levels — the brain chemical that’s in short supply in Parkinson’s disease — and could potentially protect against neurodegeneration. While the research is in the early stages, and the molecule…

Researchers characterized the structure and interactions of proteins connected to the leucine-rich repeat kinase 2 (LRRK2) gene, the most common genetic cause of Parkinson’s disease, opening up new avenues for the development of new treatments for the disease. The study,” Structural Basis for Rab8a Recruitment of…

Long-term treatment with Gocovri (amantadine) extended-release capsules was safe and led to sustained reductions in dyskinesia — involuntary, jerky movements — and off episodes in people with Parkinson’s disease, final data from a two-year Phase 3 clinical trial show. “As the longest-running amantadine study to date,…

RTB101, an investigational therapy being developed to treat Parkinson’s disease, is well-tolerated, can cross the blood-brain barrier, and reaches potentially therapeutic concentrations in cerebrospinal fluid (CSF), according to interim results of a Phase 1b/2a study. Developed by resTORbio, RTB101 is an orally-administered compound meant…